During the past decade, Hematology and Oncology Associates of Rhode Island Inc conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 11 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hematology and Oncology Associates of Rhode Island Inc" #1 sponsor was "National Cancer Institute (NCI)" with 8 trials, followed by "Celgene" with 2 trials sponsored, "Alliance for Clinical Trials in Oncology" with 1 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 1 trials sponsored and "Hoosier Cancer Research Network" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hematology and Oncology Associates of Rhode Island Inc" #1 collaborator was "Cancer and Leukemia Group B" with 3 trials as a collaborator, "NCIC Clinical Trials Group" with 3 trials as a collaborator, "National Cancer Institute (NCI)" with 3 trials as a collaborator, "SWOG Cancer Research Network" with 3 trials as a collaborator and "North Central Cancer Treatment Group" with 2 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Hematology and Oncology Associates of Rhode Island Inc" are "Breast Cancer" (2 trials), "Recurrent Breast Carcinoma" (2 trials), "Adenocarcinoma of the Colon" (1 trials), "Adenocarcinoma of the Rectum" (1 trials) and "Breast Adenocarcinoma" (1 trials). Many other conditions were trialed in "Hematology and Oncology Associates of Rhode Island Inc" in a lesser frequency.

Most popular intervention types in "Hematology and Oncology Associates of Rhode Island Inc" are "Drug" (13 trials), "Other" (8 trials), "Biological" (5 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (6 trials), "Bevacizumab" (4 trials), "fluorouracil" (4 trials), "leucovorin calcium" (3 trials) and "Letrozole" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hematology and Oncology Associates of Rhode Island Inc" are 12 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Hematology and Oncology Associates of Rhode Island Inc". undefined are not yet recruiting, undefined are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Hematology and Oncology Associates of Rhode Island Inc, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Hematology and Oncology Associates of Rhode Island Inc, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".